The prognosis of patients with bone metastasis from lung cancer has not been well documented. We assessed the survival rates after bone metastasis and prognostic factors in 118 patients with bone metastases from lung cancer. The cumulative survival rates after bone metastasis from lung cancer were 59.9% at 6 months, 31.6% at 1 year, and 11.3% at 2 years. The mean survival was 9.7 months (median, 7.2 months; range, 0.1-74.5 months). A favorable prognosis was more likely in women and patients with adenocarcinoma, solitary bone metastasis, no metastases to the appendicular bone, no pathologic fractures, performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor. Analyses of single and multiple variables indicated better prognoses for patients with adenocarcinoma, no evidence of appendicular bone metastases, and treatment with an epithelial growth factor receptor inhibitor. The mean survival period was longer in a small group treated with an epithelial growth factor receptor inhibitor than in the larger untreated group. The data preliminarily suggest treatment with an epithelial growth factor receptor inhibitor may improve survival after bone metastasis.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
0% Article relates to my practice (0/1)
0% Article does not relate to my practice (0/1)
100% Undecided (1/1)
2

Will this article lead to more cost-effective healthcare?

100% Yes (1/1)
0% No (0/1)
0% Undecided (0/1)
3

Was this article biased? (commercial or personal)

100% Yes (1/1)
0% No (0/1)
0% Undecided (0/1)
4

What level of evidence do you think this article is?

0% Level 1 (0/1)
100% Level 2 (1/1)
0% Level 3 (0/1)
0% Level 4 (0/1)
0% Level 5 (0/1)